View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2012	Feb. 01, 2013	Jun. 30, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	SANGAMO BIOSCIENCES INC
Entity Central Index Key	0001001233
Document Type	10-K
Document Period End Date	Dec. 31, 2012
Amendment Flag	false
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 277,748,267
Entity Common Stock, Shares Outstanding		53,353,402

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 21,679	$ 16,766
Marketable securities	41,868	67,366
Interest receivable	190	331
Accounts receivable	4,129	919
Other current assets	203
Prepaid expenses	296	310
Total current assets	68,365	85,692
Marketable securities, non-current	12,584
Property and equipment, net	1,543	1,603
Other assets	41	41
Total assets	82,533	87,336
Current liabilities:
Accounts payable and accrued liabilities	4,013	5,515
Accrued compensation and employee benefits	2,473	1,672
Deferred revenues	2,304	17
Total current liabilities	8,790	7,204
Deferred revenue, non-current	8,847
Total liabilities	17,637	7,204
Commitments and contingencies
Stockholders' equity:
Common stock, $0.01 par value; 80,000,000 shares authorized, 53,058,525 and 52,554,795 shares issued and outstanding at December 31, 2012 and 2011, respectively	531	526
Additional paid-in capital	339,848	332,839
Accumulated deficit	(275,509)	(253,245)
Accumulated other comprehensive income	26	12
Total stockholders' equity	64,896	80,132
Total liabilities and stockholders' equity	$ 82,533	$ 87,336

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2012	Dec. 31, 2011
Consolidated Balance Sheets [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	53,058,525	52,554,795
Common stock, shares outstanding	53,058,525	52,554,795

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenues:
Collaboration agreements	$ 18,186	$ 6,110	$ 16,819
Research grants	3,469	4,209	3,986
Total revenues	21,655	10,319	20,805
Operating expenses:
Research and development	31,709	32,098	33,154
General and administrative	12,144	14,042	12,586
Total operating expenses	43,853	46,140	45,740
Loss from operations	(22,198)	(35,821)	(24,935)
Other income (expense), net	(66)	71	81
Net loss	$ (22,264)	$ (35,750)	$ (24,854)
Basic and diluted net loss per share	$ (0.42)	$ (0.71)	$ (0.55)
Shares used in computing basic and diluted net loss per share	52,741	50,512	45,167

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Consolidated Statements of Comprehensive Loss [Abstract]
Net loss	$ (3,478)	$ (5,790)	$ (5,728)	$ (7,268)	$ (6,359)	$ (9,554)	$ (10,259)	$ (9,578)	$ (22,264)	$ (35,750)	$ (24,854)
Change in unrealized gain (loss) on available-for-sale securities									14	18	(24)
Comprehensive loss									$ (22,250)	$ (35,732)	$ (24,878)

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

- Definition

Net of tax amount of unrealized holding gain (loss) before reclassification adjustments and transfers on available-for-sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Underwritten public offering	Common Stock	Common Stock Underwritten public offering	Additional Paid-in Capital	Additional Paid-in Capital Underwritten public offering	Accumulated deficit	Accumulated Other Comprehensive Income/(Loss)
Balances at Dec. 31, 2009	$ 71,782		$ 450		$ 263,955		$ (192,641)	$ 18
Balances, shares at Dec. 31, 2009			44,994,409
Issuance of common stock upon exercise of stock options and in connection with restricted stock units	738		$ 2		736
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, shares			249,156
Issuance of common stock under employee stock purchase plan	447		$ 2		445
Issuance of common stock under employee stock purchase plan, shares			134,174
Stock-based compensation	7,818				7,818
Comprehensive loss:
Net unrealized gain (loss) on marketable securities	(24)							(24)
Net loss	(24,854)						(24,854)
Comprehensive loss	(24,878)
Balances at Dec. 31, 2010	55,907		$ 454		272,954		(217,495)	(6)
Balances, shares at Dec. 31, 2010			45,377,739
Issuance of common stock in connection with underwritten public offering		$ 50,219		$ 67		$ 50,152
Issuance of common stock in connection with underwritten public offering, shares				6,700,000
Issuance of common stock upon exercise of stock options and in connection with restricted stock units	1,194		$ 3		1,191
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, shares			324,416
Issuance of common stock under employee stock purchase plan	463		$ 2		461
Issuance of common stock under employee stock purchase plan, shares			152,640
Stock-based compensation	8,081				8,081
Comprehensive loss:
Net unrealized gain (loss) on marketable securities	18							18
Net loss	(35,750)						(35,750)
Comprehensive loss	(35,732)
Balances at Dec. 31, 2011	80,132		$ 526		332,839		(253,245)	12
Balances, shares at Dec. 31, 2011			52,554,795
Issuance of common stock upon exercise of stock options and in connection with restricted stock units	1,219		$ 3		1,216
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, shares			328,355
Issuance of common stock under employee stock purchase plan	457		$ 2		455
Issuance of common stock under employee stock purchase plan, shares			175,375
Stock-based compensation	5,338				5,338
Comprehensive loss:
Net unrealized gain (loss) on marketable securities	14							14
Net loss	(22,264)						(22,264)
Comprehensive loss	(22,250)
Balances at Dec. 31, 2012	$ 64,896		$ 531		$ 339,848		$ (275,509)	$ 26
Balances, shares at Dec. 31, 2012			53,058,525

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Operating activities:
Net loss	$ (22,264)	$ (35,750)	$ (24,854)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	660	646	676
Amortization of premium/discount on marketable securities	889	1,576	1,187
Stock-based compensation	5,338	8,081	7,818
Net loss on disposal of property and equipment	123
Net changes in operating assets and liabilities:
Interest receivable	141	6	4
Accounts receivable	(3,414)	(553)	(297)
Prepaid expenses and other assets	14	(13)	97
Accounts payable and accrued liabilities	(1,503)	(139)	3,196
Accrued compensation and employee benefits	800	315	(28)
Deferred revenue	11,134	(64)	(11,733)
Net cash used in operating activities	(8,082)	(25,895)	(23,934)
Investing activities:
Purchases of marketable securities	(91,428)	(112,974)	(100,027)
Maturities of marketable securities	103,470	83,412	113,096
Proceeds from sales of marketable securities		10,139
Purchases of property and equipment	(723)	(576)	(695)
Net cash provided by / (used in) investing activities	11,319	(19,999)	12,374
Financing activities:
Proceeds from issuance of common stock	1,676	51,876	1,185
Net cash provided by financing activities	1,676	51,876	1,185
Net increase / (decrease) in cash and cash equivalents	4,913	5,982	(10,375)
Cash and cash equivalents, beginning of period	16,766	10,784	21,159
Cash and cash equivalents, end of period	$ 21,679	$ 16,766	$ 10,784

Organization and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2012

Organization and Summary of Significant Accounting Policies [Abstract]

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Sangamo

Sangamo BioSciences, Inc. (the Company or Sangamo) was incorporated in the State of Delaware on June 22, 1995 and is focused on the research, development and commercialization of novel therapeutic strategies for unmet medical needs. Sangamo’s gene regulation and gene modification technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins (ZFPs). Potential applications of Sangamo’s technology include development of human therapeutics, plant agriculture and enhancement of pharmaceutical protein production. Sangamo will require additional financial resources to complete the development and commercialization of its products including ZFP Therapeutics.

Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds received under research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and investments as of December 31, 2012, along with expected revenues collaborations and strategic partnerships, will be adequate to fund its operations at least through 2013. Sangamo will need to raise substantial additional capital to fund subsequent operations and complete the development and commercialization of its products either through significant corporate partnerships, research grants or issuance of debt or equity securities. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company’s business and ability to develop its technology and ZFP Therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilutions to the Company’s stockholders, and any debt financing may include covenants that restrict the Company’s business.

Basis of Presentation

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates. The consolidated financial statements include the accounts of Sangamo and its wholly owned subsidiary, Gendaq Limited, after elimination of all intercompany balances and transactions.

Cash and Cash Equivalents

Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of deposits in money market investment accounts, government sponsored entity debt securities, US Treasury debt securities and corporate bank accounts.

Marketable Securities

Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income.

The Company’s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company’s cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other (expense)/income, which is determined using the specific identification method.

Fair Value of Financial Instruments

The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investment securities consist of the US Treasury, various major corporations, governmental agencies and financial institutions with high credit standing.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets (generally three to five years). For leasehold improvements, depreciation is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property, plant and equipment assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

Revenue Recognition

Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee’s product sales.

Multiple Element Arrangements prior to the adoption of ASU No. 2009-13, Revenue Recognition—Multiple Deliverable Revenue Arrangements (ASU 2009-13). For revenue arrangements entered into before January 1, 2011, that include multiple deliverables, the elements of such agreement were divided into separate units of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis.

Multiple Element Arrangements after the adoption of ASU 2009-13. ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to:

•

provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements;

•

require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence (“VSOE”), if available; third-party evidence (“TPE”), if available and VSOE is not available; or the best estimate of selling price (“ESP”), if neither VSOE nor TPE is available; and

•

eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method.

For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January 1, 2011, the Company will allocate revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreement entered into with Shire AG (Shire) in January 2012 was evaluated under these amended accounting standards.

Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that objectives will be achieved and if the achievement is based on the Company’s performance.

Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received which have not been earned.

Sangamo’s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred.

During 2012, revenues related to Shire, Sigma-Aldrich Corporation (Sigma) and Dow AgroSciences LLC (DAS) represented 51%, 11% and 22%, respectively, of total revenues. During 2011, revenues related to Sigma, DAS, California Institute for Regenerative Medicine (CIRM) and CHDI Foundation, Inc. (CHDI) represented 15%, 43%, 18% and 11% of total revenues, respectively. During 2010, revenues related to Sigma and DAS represented 59% and 21%, respectively, of total revenues.

Research and Development Expenses

Research and development costs are expensed as incurred. Research and development expenses consist of direct and research-related allocated overhead costs such as facilities costs, salaries and related personnel costs, and material and supply costs. In addition, research and development expenses include costs related to clinical trials, validation of the Company’s testing processes and procedures and as well as related overhead expenses. Research and development costs incurred in connection with collaborator-funded activities are expensed as incurred. Costs to acquire technologies that are utilized in research and development that have no alternative future use are expensed as incurred.

Stock-Based Compensation

The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stuck units (RSUs) and employee share purchases related to the Employee Share Purchase Plan (ESPP), based on estimated fair values at grant date. The fair value of equity-based awards is amortized over the vesting period of the award using a straight-line method.

To estimate the value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company’s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. Further, the Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest.

Income Taxes

Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.

Net Loss Per Share

Basic net loss per share has been computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive securities outstanding during the period.

Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of options, which are all anti-dilutive. The total stock options outstanding excluded from the calculation of diluted net loss per share at the end of 2012, 2011 and 2010 were 9,184,346, 8,346,190 and 8,109,901, respectively.

Segments

The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. As of December 31, 2012 and 2011, all of the Company’s assets were maintained in the U.S. For the years ended December 31, 2012, 2011 and 2010, 100% of revenues and operating expenses were generated and incurred in the U.S.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References + Details

Investments and Fair Value Measurement

12 Months Ended

Dec. 31, 2012

Investments and Fair Value Measurement [Abstract]

INVESTMENTS AND FAIR VALUE MEASUREMENT

NOTE 2 – INVESTMENTS AND FAIR VALUE MEASUREMENT

The table below summarizes the Company’s available-for-sale securities (in thousands):


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized (Losses)			Estimated Fair Value
December 31, 2012
Cash equivalents:
U.S. government sponsored entity debt securities	$	2,997	$	—	$	—		$	2,997
Money market funds		15,839		—		—			15,839

Total		18,836		—		—			18,836

Marketable securities:
U.S. government sponsored entity debt securities		54,426		26		—			54,452

Total		54,426		26		—			54,452

Total cash equivalents and marketable securities	$	73,262	$	26	$	—		$	73,288

December 31, 2011
Cash equivalents:
Money market funds	$	15,258		—		—		$	15,258

Total		15,258		—		—			15,258

Marketable securities:
U.S. government sponsored entity debt securities		27,020		—		(7	)		27,013
U.S. treasury debt securities		751		1		—			752
Corporate debt securities		39,583		18		—			39,601

Total		67,354		19		(7	)		67,366

Total cash equivalents and marketable securities	$	82,612	$	19	$	(7	)	$	82,624

As of December 31, 2012, all of investments had maturity dates within two years and there were no material unrealized losses during 2012. Approximately 83% of the Company’s available-for-sale securities mature within the next twelve months of the date of the balance sheet date and approximately 17% of the Company’s available-for-sale securities have maturities between twelve and twenty-four months from the date of the balance sheet date. The Company had no material realized losses or other-than-temporary impairments of available-for-sale securities for the years ended December 31, 2012, 2011 and 2010.

Fair Value Measurement

The Company measures certain financial assets at fair value on a recurring basis, including cash equivalents and available-for-sale securities. The fair value of these assets was determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

When observable market prices for identical securities that are traded in less active markets are used, the Company classifies its available-for-sale debt instruments as Level 2. When observable market prices for identical securities are not available, available-for-sale debt instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, and matrix pricing as well as model processes. These models are proprietary valuation models of pricing providers or brokers. These valuation models incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the Standard Inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.

The fair value measurements of cash equivalents and available-for-sale marketable securities are identified at the following levels within the fair value hierarchy (in thousands):


	December 31, 2012 Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
U.S. government sponsored entity debt securities	$	2,997	$	—	$	2,997	$	—
Money market funds		15,839		15,839		—		—

Total		18,836		15,839		2,997		—
Marketable securities:
U.S. government sponsored entity debt securities		54,452		—		54,452		—

Total		54,452		—		54,452		—

Total cash equivalents and marketable securities	$	73,288	$	15,839	$	57,449	$	—


	December 31, 2011 Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	15,258	$	15,258	$	—	$	—

Total		15,258		15,258		—		—
Marketable securities:
U.S. government sponsored entity debt securities		27,013		—		27,013		—
U.S. treasury debt securities		752		—		752		—
Corporate debt securities		39,601		—		39,601		—

Total		67,366		—		67,366		—

Total cash equivalents and marketable securities	$	82,624	$	15,258	$	67,366	$	—

Stock-Based Compensation

12 Months Ended

Dec. 31, 2012

Stock-Based Compensation [Abstract]

STOCK-BASED COMPENSATION

NOTE 3 – STOCK-BASED COMPENSATION

The following table shows total stock-based compensation expense recognized in the consolidated statements of operations (in thousands):


	Year Ended December 31,
	2012		2011		2010
Research and development	$	2,892	$	3,769	$	3,612
General and administrative		2,446		4,312		4,206

Total stock-based compensation expense	$	5,338	$	8,081	$	7,818

As of December 31, 2012, total stock-based compensation expense related to unvested stock options to be recognized in future periods was $9.8 million, which is expected to be expensed over a weighted-average period of 2.79 years. As of December 31, 2012, total compensation expense related to unvested RSUs to be recognized in future periods was $3.5 million, which is expected to be expensed over a weighted-average period of 2.40 years. There was no capitalized stock-based employee compensation expense as of December 31, 2012.

Valuation Assumptions

The employee stock-based compensation expense was determined using the Black-Scholes option valuation model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time.

The Company primarily bases its determination of expected volatility through its assessment of the historical volatility of its common stock. The Company relied on its historical exercise and post-vested termination activity for estimating its expected term for use in determining the fair value of these options.

The weighted-average estimated fair value per share of options granted during 2012, 2011 and 2010 was $3.76, $3.20 and $3.85, respectively, based upon the assumption in the Black-Scholes valuation model. The weighted–average assumptions used for estimating the fair value of the employee stock options are as follows:


	Year Ended December 31,
	2012			2011			2010
Risk-free interest rate		0.74-1.34	%		0.93-2.11	%		1.5-2.6	%
Expected life of option (in years)		5.40-5.58			5.39-5.41			5.23-5.41
Expected dividend yield of stock		0	%		0	%		0	%
Expected volatility		0.87-0.88			0.83-0.86			0.83-0.84

Employees purchased approximately 175,000, 153,000 and 134,000 shares of common stock through the 2010 Purchase Plan at an average exercise price of $2.61, $3.02 and $3.34 per share during the fiscal years 2012, 2011 and 2010, respectively.

The weighted-average estimated fair value of shares purchased under the Company’s ESPP during 2012, 2011 and 2010 were $2.51, $1.62 and $2.76, respectively, based upon the assumptions in the Black-Scholes valuation model. The weighted–average assumptions used for estimating the fair value of the ESPP purchase rights are as follows:


	Year Ended December 31,
	2012			2011			2010
Risk-free interest rate		0.05-0.30	%		0.05-0.61	%		0.2-1.0	%
Expected life of option (in years)		0.5-2.0			0.5-2.0			0.5-2.0
Expected dividend yield of stock		0	%		0	%		0	%
Expected volatility		0.93-1.37			0.58-0.85			0.62-1.14

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Major Customers, Partnerships and Strategic Alliances

12 Months Ended

Dec. 31, 2012

Major Customers, Partnerships and Strategic Alliances [Abstract]

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES

NOTE 4 – MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES

Collaboration Agreements

Collaboration and License Agreement with Shire AG in Human Therapeutics and Diagnostics

On January 31, 2012, the Company entered into a collaboration and license agreement (the Agreement) with Shire AG (Shire), pursuant to which the Company and Shire collaborate to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on Sangamo’s novel ZFP technology. Under the Agreement, the Company and Shire may develop potential human therapeutic or diagnostic products for seven gene targets. The initial four gene targets selected were blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets will be used for treating or diagnosing hemophilia. In June 2012, Shire selected a fifth gene target for the development of a ZFP therapeutic for Huntington’s disease, an inherited neurodegenerative disease for which there are currently no therapies available to slow the disease progression. Shire has the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the Agreement, the Company granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use Sangamo’s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets. The initial research term of the Agreement is six years and is subject to extensions upon mutual agreement and under other specified circumstances.

Under the terms of the Agreement, the Company is responsible for all research activities through the submission of an Investigative New Drug Application (IND) or European Clinical Trial Application (CTA), while Shire is responsible for clinical development and commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. Shire reimburses Sangamo for its internal and external research program-related costs.

The Company received an upfront license fee of $13.0 million. The Company will also be eligible to receive up to $213.5 million of contingent payments for each gene target if specified research, regulatory, clinical development, commercialization and sales milestone events occur, including payments for each gene target through the acceptance of an IND or CTA submission totaling $8.5 million. The Company will also be eligible to receive royalty payments that are a tiered double-digit percentage of net sales of licensed product sold by Shire or its sublicensees developed under the collaboration, if any. To date, no products have been approved and therefore no royalty fees have been earned under the Agreement with Shire.

All contingent payments under the Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Agreement with Shire based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are substantive milestones because they are related to events (i) that can be achieved based in whole or in part on either the Company’s performance or on the occurrence of a specific outcome resulting from the Company’s performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii) that would result in additional payments being due to the Company. Accordingly, revenue for these achievements will be recognized in its entirety in the period when the milestone is achieved and collectability is reasonably assured.

The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Shire apart from the research services to be performed pursuant to the Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a six-year initial research term during which the Company will perform research services. As of December 31, 2012, the Company has deferred revenue of $11.1 million related to this Agreement.

Revenues recognized under the agreement with Shire for the twelve months ended December 31, 2012, were as follows (in thousands):


	Year ended December 31, 2012
Revenues related to Shire Collaboration:
Amortization of upfront fee	$	1,986
Research services		9,026

Total	$	11,012

Related costs and expenses incurred under the Shire agreement were $7.7 million during the twelve months ended December 31, 2012.

Agreement with Sigma-Aldrich Corporation in Laboratory Research Reagents, Transgenic Animal and Commercial Protein Production Cell-line Engineering

In July 2007, Sangamo entered into a license agreement with Sigma. Under the license agreement, Sangamo agreed to provide Sigma with access to its proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC. Under the agreement, Sangamo and Sigma agreed to conduct a three-year research program to develop laboratory research reagents using Sangamo’s ZFP technology during which time Sangamo agreed to assist Sigma in connection with its efforts to market and sell services employing the Company’s ZFP technology in the research field. Sangamo has transferred the ZFP manufacturing technology to Sigma.

In October 2009, Sangamo expanded its license agreement with Sigma. In addition to the original terms of the license agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $20.0 million consisting of a $4.9 million purchase of 636,133 shares of Sangamo common stock, valued at $4.9 million, and a $15.1 million upfront license fee. The upfront license fee was recognized on a straight-line basis from the effective date of the expanded license through July 2010, which represents the period over which Sangamo was obligated to perform research services for Sigma. Sangamo is also eligible to receive commercial license fees of $5.0 million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones Sigma will make milestone payments to Sangamo up to an aggregate of $25.0 million.


	Year ended December 31,
	2012		2011		2010
Revenue related to Sigma Collaboration:
Royalty revenues	$	1,288	$	938	$	734
License fee and milestone revenues		1,000		671		11,574

Total		2,288		1,609		12,308

Related costs and expenses incurred under the Sigma agreement were $0.3 million, $0.5 million and $1.2 million during 2012, 2011 and 2010, respectively.

Agreement with Dow AgroSciences in Plant Agriculture

In October 2005, Sangamo entered into an exclusive commercial license with DAS. Under this agreement, Sangamo is providing DAS with access to its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP transcription factors (ZFP TFs) or ZFP nucleases (ZFNs) into humans or animals for diagnostic, therapeutic, or prophylactic purposes. The Company’s agreement with DAS provided for an initial three-year research term. In June 2008, DAS exercised its option under the agreement to obtain a commercial license to sell products incorporating or derived from plant cells generated using the Company’s ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals. The exercise of the option triggered a one-time commercial license fee of $6.0 million, payment of the remaining $2.3 million of the previously agreed $4.0 million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo’s ZFP technology to third parties for use in plant cells, plants, or plant cell cultures, and Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December 31, 2012.

The agreement also provides for minimum sublicense fees each year due to Sangamo every October, provided the agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million and total $25.3 million over 11 years. The Company does not have any performance obligations with respect to the sublicensing activities to be conducted by DAS. DAS has the right to terminate the agreement at any time; accordingly, the Company’s actual sublicense fees over the term of the agreement could be lower than $25.3 million. In addition, each party may terminate the agreement upon an uncured material breach of the agreement by the other party. In the event of any termination of the agreement, all rights to use the Company’s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo’s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company’s ZFP technology.

Revenues under the agreement were $4.7 million, $4.5 million and $4.4 million during 2012, 2011 and 2010, respectively. Related costs and expenses incurred under the agreement were $0.6 million, $0.9 million and $0.7 million during 2012, 2011 and 2010, respectively.

Funding from Research Foundations

California Institute for Regenerative Medicine

In October 2009, the CIRM, a State of California entity, granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of ZFN gene-editing technology in stem cells. The four year grant supports an innovative research project conducted by a multidisciplinary team of investigators, including investigators from the University of Southern California, City of Hope National Medical Center and Sangamo BioSciences. Sangamo expects to receive funding up to $5.2 million from the total amount awarded based on expenses incurred for research and development efforts by Sangamo as prescribed in the agreement, and subject to its terms and conditions. The award is intended to substantially fund Sangamo’s research and development efforts related to the agreement. The State of California has the right to receive, subject to the terms and conditions of the agreement between Sangamo and CIRM, payments from Sangamo resulting from sales of a commercial product resulting from research and development efforts supported by the grant, not to exceed two times the amount Sangamo receives in funding under the agreement with CIRM.

Revenues attributable to research and development performed under the CIRM grant agreement for AIDS-related lymphoma therapy were $1.2 million, $1.7 million and $1.0 million during 2012, 2011 and 2010, respectively. Related costs during 2012, 2011 and 2010 were $1.2 million, $2.0 million and $1.0 million, respectively.

CHDI Foundation, Inc.

In April 2011, Sangamo entered into an agreement with the CHDI to develop a novel therapeutic for Huntington’s disease based on Sangamo’s proprietary ZFP technology. The ZFP therapeutic approach targets the gene that causes Huntington’s disease, an inherited neurodegenerative disease for which there are currently no therapies available to slow the disease progression. Under the agreement with CHDI, and subject to its terms and conditions, CHDI paid the Company $1.3 million, the total funds due under the agreement, over a period of one year which is intended to substantially fund the Company’s research efforts related to the agreement. During 2012, the agreement was amended to extend the project through August 2012 and to increase total potential funding from $1.3 million to $2.1 million, plus reimbursement for certain direct expenses related to the project. The agreement with CHDI terminated on August 31, 2012.

Revenues attributable to research and development performed under the CHDI collaboration agreement were $1.1 million during 2012 and 2011. Related costs during 2012 and 2011 were $1.1 million and $1.2 million, respectively.

The Juvenile Diabetes Research Foundation International

In October 2006, Sangamo entered into an agreement with the Juvenile Diabetes Research Foundation International (JDRF) to provide financial support for one of Sangamo’s Phase 2 human clinical studies of the Company’s product candidate SB-509, a ZFP Therapeutic that was in development for the treatment of diabetic neuropathy. In January 2010, JDRF and Sangamo amended the agreement and, subject to its terms and conditions, JDRF agreed to provide additional funding of up to $3.0 million for a Phase 2b trial in diabetic neuropathy.

In October 2011, the Company announced that it would not pursue additional clinical development of the SB-509 program. In March 2012, the Company received a final payment of $0.8 million for work performed under the agreement. The Company does not expect to receive additional funding under the agreement.

Revenues attributable to research and development activities performed under the JDRF agreements were $0.8 million, $0.5 million and $1.5 million during 2012, 2011 and 2010, respectively.

The Michael J. Fox Foundation for Parkinson’s Research

In January 2007, the Company entered into a partnership with the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to provide financial support of the Company’s program to develop ZFP TFs to activate the expression of glial cell line-derived neurotrophic factor (GDNF). Under the agreement with MJFF and subject to its terms and conditions, MJFF paid the Company $1.0 million, the total funds due under the agreement. In June 2010, the Company received a commitment for additional funding of $0.9 million from MJFF to support further studies of ZFP TF activators of GDNF and intended to substantially fund Sangamo research efforts related to the agreement. As of 2012 the Company has received the entire $1.9 million in funding available under the agreements with MJFF and does not expect to receive any further funding under this agreement.

Revenues attributable to research and development performed under the MJFF agreement were $0.4 million in 2011 and 2010. There were no such revenues in 2012.

Funding from Other Sources

Qualifying Therapeutic Discovery Project Program

In October 2010, Sangamo was awarded a total of $1.0 million in grants for four qualifying therapeutic discovery projects under the Patient Protection and Affordable Care Act. There was no such funding in 2012 or 2011.

Property and Equipment

12 Months Ended

Dec. 31, 2012

Property and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment consist of the following (in thousands):


	December 31,
	2012			2011
Laboratory equipment	$	2,950		$	2,851
Furniture and fixtures		499			442
Leasehold improvements		1,046			1,036

		4,495			4,329
Less accumulated depreciation		(2,952	)		(2,726	)

	$	1,543		$	1,603

Depreciation expense was $0.6 million for 2012 and 2011, and $0.7 million for 2010. In 2012, the Company disposed of $0.5 million in fixed assets with associated accumulated depreciation of $0.4 million. The Company recognized a $0.1 million loss on the write-off of these assets.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Commitments

12 Months Ended

Dec. 31, 2012

Commitments [Abstract]

COMMITMENTS

NOTE 6 – COMMITMENTS

Sangamo occupies office and laboratory space under operating leases in Richmond, California that expire in August 2014. Rent expenses were $0.6 million for 2012, 2011 and 2010. Future minimum payments under contractual obligations at December 31, 2012 consist of the following (in thousands):


Fiscal Year:	Operating Lease
2013		616
2014		417
Thereafter		—

Total minimum payments	$	1,033

Stockholders' Equity

12 Months Ended

Dec. 31, 2012

Stockholders' Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 7 – STOCKHOLDERS’ EQUITY

Preferred Stock

The Company has 5,000,000 preferred shares authorized, which may be issued at the Board’s discretion.

Common Stock

In April 2011, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 6,700,000 shares of its common stock at a public offering price of $7.70 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $50.2 million.

Stock Incentive Plan

Sangamo’s 2004 Stock Incentive Plan (the 2004 Plan), which supersedes the 2000 Stock Incentive Plan (the 2000 Plan), provides for the issuance of common stock and grants of options to purchase shares of common stock to employees, officers, directors and consultants. The option exercise price per share will generally not be less than 100 percent of the fair value per share of common stock on the option grant date, and the option term will not exceed ten years. If the person to whom the option is granted is a 10 percent stockholder, and the option granted qualifies as an Incentive Stock Option Grant, then the exercise price per share will not be less than 110 percent of the fair value per share of common stock on the option grant date, and the option term will not exceed five years. Options granted under the 2004 Plan generally vest over four years at a rate of 25 percent one year from the grant date and one thirty-sixth per month thereafter and expire ten years after the grant, or earlier upon employment termination. Certain options granted under the 2004 Plan to the Company’s non-employee directors have been structured so that they may be exercised prior to vesting, with the related shares subject to Sangamo’s right to repurchase any shares that have not vested pursuant to the vesting schedule in effect for such award at the exercise price paid if the option holder’s board service terminates. Approximately 6.5 million shares were initially reserved for issuance pursuant to the 2000 Plan and the 2004 Plan. The number of shares authorized for issuance under the 2004 Plan automatically increases on the first trading day of the fiscal year by an amount equal to 3% of the total number of shares of the Company’s common stock outstanding on the last trading day of the preceding fiscal year, but in no event shall any such increase exceed 1.75 million shares per year. During 2012, 2011 and 2010, 1,576,644, 1,361,332 and 1,349,832 additional shares, respectively, were authorized for issuance under the 2004 Plan pursuant to the evergreen increase feature of such plan.

Employee Stock Purchase Plan

Sangamo’s 2010 Employee Stock Purchase Plan (Purchase Plan), which supersedes the 2000 Employee Stock Purchase Plan, provides a total reserve of 2,100,000 shares of common stock for issuance under the Purchase Plan. Eligible employees may purchase common stock at 85 percent of the lesser of the fair market value of Sangamo’s common stock on the first day of the applicable two-year offering period or the last day of the applicable six-month purchase period.

Stock Option Activity

A summary of Sangamo’s stock option activity is as follows:


	Number of Shares			Weighted- Average Exercise per Share Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
						(In years)		(In thousands)
Options outstanding at December 31, 2011		8,374,190		$	6.28		6.78
Options granted		1,352,150		$	5.38
Options exercised		(326,688	)	$	3.73
Options canceled		(215,306	)	$	7.04

Options outstanding at December 31, 2012		9,184,346		$	6.21		6.46	$	8,821

Options vested and expected to vest at December 31, 2012		8,806,544		$	6.25		6.31	$	8,523
Options exercisable at December 31, 2012		6,435,730		$	6.62		5.41	$	6,679

Newly created shares are issued upon exercise of options. There were no shares subject to Sangamo’s right of repurchase as of December 31, 2012. The intrinsic value of options exercised was $0.6 million, $1.0 million and $0.5 million during 2012, 2011 and 2010, respectively.

At December 31, 2012, the aggregate intrinsic values of the outstanding and exercisable options were $8.8 million and $6.7 million, respectively. The aggregate intrinsic value of shares vested and expected to vest during 2012, 2011 and 2010 was $8.5 million, $0.1 million and $11.2 million, respectively.

The following table summarizes information with respect to stock options outstanding at December 31, 2012:


	Options Outstanding and Exercisable				Options Exercisable
Range of Exercise Price	Number of Shares of common stock subject to options		Weighted Average Remaining Contractual Life		Number of Shares of common stock subject to options		Weighted Average Exercise Price
			(In years)
$ 2.04 – $ 3.42		366,394		8.31		107,603	$	2.55
$ 3.45 – $ 3.45		1,613,813		5.94		1,613,813	$	3.45
$ 3.61 – $ 5.19		1,045,182		3.67		912,138	$	4.47
$ 5.26 – $ 5.30		7,500		8.03		1,500	$	5.30
$ 5.35 – $ 5.35		1,126,273		6.93		838,523	$	5.35
$ 5.41 – $ 5.41		1,186,650		9.93		—	$	—
$ 5.42 – $ 5.66		60,500		6.24		56,333	$	5.46
$ 5.70 – $ 5.70		1,132,851		7.94		565,551	$	5.70
$ 5.86 – $ 6.82		1,054,230		5.88		785,006	$	6.49
$ 6.88 – $14.62		1,590,953		4.80		1,555,263	$	12.59

		9,184,346		6.46		6,435,730	$	6.62

Restricted Stock Units

During 2012, the Company issued 486,750 Restricted Stock Units (RSUs) under the Company’s 2004 Stock Incentive Plan at a grant date fair value of $5.41. These awards will vest as follows: one-third of the award will vest in a series of three successive equal annual installments. During 2011, the Company issued 550,000 RSUs under the Company’s 2004 Stock Incentive Plan at a grant date fair value of $2.55. These awards will vest as follows: one-third of the award will vest on the second anniversary of the award date and two-thirds of the award will vest on the third anniversary of the award date. During 2010, the Company issued 10,000 RSUs under the Company’s 2004 Stock Incentive Plan at a grant date fair value of $6.05. These RSUs vested in equal monthly installments over a two-year service period. Fair value of restricted stock units are estimated based upon the closing sales price of the Company’s common stock on the grant date. There were 1,036,750 and 551,667 RSUs outstanding under the Company’s stock option plans as of December 31, 2012 and 2011, respectively. The aggregate value of shares vested during 2012, 2011 and 2010 was $0.1 million, $0.2 million and $0.1 million, respectively.

A summary of Sangamo’s restricted stock unit activity is as follows:


	Number of Shares			Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
				(In years)		(In thousands)
RSUs outstanding at December 31, 2011		551,667
RSUs awarded		486,750
RSUs released		(1,667	)
RSUs forfeited		0

RSUs outstanding at December 31, 2012		1,036,750			1.76	$	6,231

RSUs vested and expected to vest at December 31, 2012		835,782			1.76	$	5,023

As of December 31, 2012, 2,749,117 shares were reserved for future awards under the Company’s stock incentive plans. As of December 31, 2012, there were 1,708,315 shares of common stock reserved for future issuance under the 2010 Employee Stock Purchase Plan.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2012

Income Taxes [Abstract]

INCOME TAXES

NOTE 8 – INCOME TAXES

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows (in thousands):


	December 31,
	2012			2011
Deferred tax assets:
Net operating loss carryforwards	$	73,129		$	67,395
Research and development tax credit carryforwards		6,770			6,844
Capitalized research		5			117
Stock-based compensation		7,375			7,355
Other		937			1,125

		88,216			82,836
Valuation allowance		(88,216	)		(82,836	)

Net deferred tax assets	$	—		$	—

Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $5.4 million, $19.7 million and $7.4 million for the years ended December 31, 2012, 2011 and 2010, respectively. As of December 31, 2012, Sangamo had net operating loss carryforwards for federal and state income tax purposes of approximately $187.1 million and $163.1 million, respectively. If not utilized, the net federal and state operating loss carryforwards will begin to expire in 2013. The Company also has federal and state research tax credit carryforwards of $5.1 million and $5.9 million, respectively. The federal research credits will begin to expire in 2018 while the state research credits have no expiration date. Utilization of the Company’s net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before use.

The Company files U.S and state income tax returns with varying statutes of limitations. The tax years from 1998 forward remain open to examination due to the carryover of net operating losses or tax credits. The Company also files various foreign income tax returns with varying statutes of limitations, and the tax years from 2006 and thereafter remain open to examination.

The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31 2012, the Company had no accrued interest and/or penalties. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. In the event that any unrecognized tax benefits are recognized, the effective tax rate will not be affected.

The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands):


	December 31,
	2012			2011		2010
Beginning balance	$	2,750		$	1,896	$	1,643
Additions based on tax positions related to the current year		153			589		253
Additions for tax positions of prior years		58			265		—
Reductions for tax positions of prior years		(227	)		—		—

Ending balance	$	2,734		$	2,750	$	1,896

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

Accounts Payable and Accrued Liabilities

12 Months Ended

Dec. 31, 2012

Accounts Payable and Accrued Liabilities [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE 9 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities consist of the following (in thousands):


	December 31,
	2012		2011
Accounts payable	$	3,046	$	4,110
Accrued clinical trial expense		615		968
Accrued professional fees		238		299
Deferred rent		94		131
Other		20		7

Total accounts payable and accrued liabilities	$	4,013	$	5,515

Employee Benefit Plan

12 Months Ended

Dec. 31, 2012

Employee Benefit Plan [Abstract]

Employee Benefit Plan

NOTE 10 – EMPLOYEE BENEFIT PLAN

The Company sponsors a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code covering all full-time employees (Sangamo 401(k) Plan). The Sangamo 401(k) Plan is intended to qualify under Section 401 of the Internal Revenue Code.

In 2012, the Company matched contributions by employees equal to 50% of the first 6% of employee contributions up to a limit of $1,000. Matching funds are fully vested when contributed. Contributions to the Sangamo 401(k) Plan in the year ended December 31, 2012, were $0.1 million. There were no such contributions in 2011 or 2010.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Implementation Guide (Q and A)
-Number FAS88
-Paragraph 63
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-2
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph q
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 8
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS106-2
-Paragraph 20, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 30
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2012

Quarterly Financial Data [Abstract]

QUARTERLY FINANCIAL DATA (UNAUDITED)

NOTE 11 – QUARTERLY FINANCIAL DATA (UNAUDITED)

The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December 31, 2012. The unaudited information set forth below has been prepared on the same basis as the audited information and includes all adjustments necessary to present fairly the information set forth herein. The operating results for any quarter are not indicative of results for any future period. All data is in thousands except per common share data.


	2012												2011
	Q1			Q2			Q3			Q4			Q1			Q2			Q3			Q4
Revenues	$	3,243		$	4,574		$	4,907		$	8,931		$	2,200		$	1,514		$	1,857		$	4,748
Expenses	$	10,526		$	10,318		$	10,709		$	12,300		$	11,801		$	11,795		$	11,431		$	11,113
Net loss	$	(7,268	)	$	(5,728	)	$	(5,790	)	$	(3,478	)	$	(9,578	)	$	(10,259	)	$	(9,554	)	$	(6,359	)
Net loss per share	$	(0.13	)	$	(0.11	)	$	(0.11	)	$	(0.07	)	$	(0.21	)	$	(0.20	)	$	(0.18	)	$	(0.12	)

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details

Organization and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2012

Organization and Summary of Significant Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Cash and Cash Equivalents

Cash and Cash Equivalents

Marketable Securities

Marketable Securities

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Property and Equipment

Property and Equipment

Revenue Recognition

Revenue Recognition

Multiple Element Arrangements after the adoption of ASU 2009-13. ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to:

•

eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method.

Research and Development Expenses

Research and Development Expenses

Stock-Based Compensation

Stock-Based Compensation

Income Taxes

Income Taxes

Net Loss Per Share

Net Loss Per Share

Segments

Segments

Investments and Fair Value Measurement (Tables)

12 Months Ended

Dec. 31, 2012

Investments and Fair Value Measurement [Abstract]

Schedule of available-for-sale securities

The table below summarizes the Company’s available-for-sale securities (in thousands):


	Amortized Cost		Gross Unrealized Gains		Gross Unrealized (Losses)			Estimated Fair Value
December 31, 2012
Cash equivalents:
U.S. government sponsored entity debt securities	$	2,997	$	—	$	—		$	2,997
Money market funds		15,839		—		—			15,839

Total		18,836		—		—			18,836

Marketable securities:
U.S. government sponsored entity debt securities		54,426		26		—			54,452

Total		54,426		26		—			54,452

Total cash equivalents and marketable securities	$	73,262	$	26	$	—		$	73,288

December 31, 2011
Cash equivalents:
Money market funds	$	15,258		—		—		$	15,258

Total		15,258		—		—			15,258

Marketable securities:
U.S. government sponsored entity debt securities		27,020		—		(7	)		27,013
U.S. treasury debt securities		751		1		—			752
Corporate debt securities		39,583		18		—			39,601

Total		67,354		19		(7	)		67,366

Total cash equivalents and marketable securities	$	82,612	$	19	$	(7	)	$	82,624

Summary of fair value measurements of cash equivalents and available-for-sale marketable securities

The fair value measurements of cash equivalents and available-for-sale marketable securities are identified at the following levels within the fair value hierarchy (in thousands):


	December 31, 2012 Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
U.S. government sponsored entity debt securities	$	2,997	$	—	$	2,997	$	—
Money market funds		15,839		15,839		—		—

Total		18,836		15,839		2,997		—
Marketable securities:
U.S. government sponsored entity debt securities		54,452		—		54,452		—

Total		54,452		—		54,452		—

Total cash equivalents and marketable securities	$	73,288	$	15,839	$	57,449	$	—


	December 31, 2011 Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	15,258	$	15,258	$	—	$	—

Total		15,258		15,258		—		—
Marketable securities:
U.S. government sponsored entity debt securities		27,013		—		27,013		—
U.S. treasury debt securities		752		—		752		—
Corporate debt securities		39,601		—		39,601		—

Total		67,366		—		67,366		—

Total cash equivalents and marketable securities	$	82,624	$	15,258	$	67,366	$	—

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19, 20, 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 17
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 21
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Tabular disclosure related to assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a recurring and/or nonrecurring basis in periods after initial recognition. Disclosures include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3) as well as transfers between levels 1 and 2.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a,b,bb)
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2C
-URI http://asc.fasb.org/extlink&oid=7578670&loc=SL7498348-110258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19190-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 33
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 6
-Footnote 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2012

Stock-Based Compensation [Abstract]

Stock-based compensation expenses

The following table shows total stock-based compensation expense recognized in the consolidated statements of operations (in thousands):


	Year Ended December 31,
	2012		2011		2010
Research and development	$	2,892	$	3,769	$	3,612
General and administrative		2,446		4,312		4,206

Total stock-based compensation expense	$	5,338	$	8,081	$	7,818

Estimating the fair value of the employee stock options

The weighted–average assumptions used for estimating the fair value of the employee stock options are as follows:


	Year Ended December 31,
	2012			2011			2010
Risk-free interest rate		0.74-1.34	%		0.93-2.11	%		1.5-2.6	%
Expected life of option (in years)		5.40-5.58			5.39-5.41			5.23-5.41
Expected dividend yield of stock		0	%		0	%		0	%
Expected volatility		0.87-0.88			0.83-0.86			0.83-0.84

Summary of fair value of the employee stock options and ESPP plan

The weighted–average assumptions used for estimating the fair value of the ESPP purchase rights are as follows:


	Year Ended December 31,
	2012			2011			2010
Risk-free interest rate		0.05-0.30	%		0.05-0.61	%		0.2-1.0	%
Expected life of option (in years)		0.5-2.0			0.5-2.0			0.5-2.0
Expected dividend yield of stock		0	%		0	%		0	%
Expected volatility		0.93-1.37			0.58-0.85			0.62-1.14

Major Customers, Partnerships and Strategic Alliances (Tables)

12 Months Ended

Dec. 31, 2012

Shire AG [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues recognized under the agreement

Revenues recognized under the agreement with Shire for the twelve months ended December 31, 2012, were as follows (in thousands):


	Year ended December 31, 2012
Revenues related to Shire Collaboration:
Amortization of upfront fee	$	1,986
Research services		9,026

Total	$	11,012

Sigma-Aldrich Corporation [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues recognized under the agreement


	Year ended December 31,
	2012		2011		2010
Revenue related to Sigma Collaboration:
Royalty revenues	$	1,288	$	938	$	734
License fee and milestone revenues		1,000		671		11,574

Total		2,288		1,609		12,308

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2012

Property and Equipment [Abstract]

Summary of property and equipment

Property and equipment consist of the following (in thousands):


	December 31,
	2012			2011
Laboratory equipment	$	2,950		$	2,851
Furniture and fixtures		499			442
Leasehold improvements		1,046			1,036

		4,495			4,329
Less accumulated depreciation		(2,952	)		(2,726	)

	$	1,543		$	1,603

Commitments (Tables)

12 Months Ended

Dec. 31, 2012

Commitments [Abstract]

Summary of Future minimum payments under contractual obligations

Future minimum payments under contractual obligations at December 31, 2012 consist of the following (in thousands):


Fiscal Year:	Operating Lease
2013		616
2014		417
Thereafter		—

Total minimum payments	$	1,033

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2012

Stockholders' Equity [Abstract]

Summary of stock option activity

A summary of Sangamo’s stock option activity is as follows:


	Number of Shares			Weighted- Average Exercise per Share Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
						(In years)		(In thousands)
Options outstanding at December 31, 2011		8,374,190		$	6.28		6.78
Options granted		1,352,150		$	5.38
Options exercised		(326,688	)	$	3.73
Options canceled		(215,306	)	$	7.04

Options outstanding at December 31, 2012		9,184,346		$	6.21		6.46	$	8,821

Options vested and expected to vest at December 31, 2012		8,806,544		$	6.25		6.31	$	8,523
Options exercisable at December 31, 2012		6,435,730		$	6.62		5.41	$	6,679

Summarizes information with respect to stock options outstanding

The following table summarizes information with respect to stock options outstanding at December 31, 2012:


	Options Outstanding and Exercisable				Options Exercisable
Range of Exercise Price	Number of Shares of common stock subject to options		Weighted Average Remaining Contractual Life		Number of Shares of common stock subject to options		Weighted Average Exercise Price
			(In years)
$ 2.04 – $ 3.42		366,394		8.31		107,603	$	2.55
$ 3.45 – $ 3.45		1,613,813		5.94		1,613,813	$	3.45
$ 3.61 – $ 5.19		1,045,182		3.67		912,138	$	4.47
$ 5.26 – $ 5.30		7,500		8.03		1,500	$	5.30
$ 5.35 – $ 5.35		1,126,273		6.93		838,523	$	5.35
$ 5.41 – $ 5.41		1,186,650		9.93		—	$	—
$ 5.42 – $ 5.66		60,500		6.24		56,333	$	5.46
$ 5.70 – $ 5.70		1,132,851		7.94		565,551	$	5.70
$ 5.86 – $ 6.82		1,054,230		5.88		785,006	$	6.49
$ 6.88 – $14.62		1,590,953		4.80		1,555,263	$	12.59

		9,184,346		6.46		6,435,730	$	6.62

Summary of Restricted stock unit activity

A summary of Sangamo’s restricted stock unit activity is as follows:


	Number of Shares			Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
				(In years)		(In thousands)
RSUs outstanding at December 31, 2011		551,667
RSUs awarded		486,750
RSUs released		(1,667	)
RSUs forfeited		0

RSUs outstanding at December 31, 2012		1,036,750			1.76	$	6,231

RSUs vested and expected to vest at December 31, 2012		835,782			1.76	$	5,023

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2012

Income Taxes [Abstract]

Schedule of company's deferred tax assets

Significant components of the Company’s deferred tax assets are as follows (in thousands):


	December 31,
	2012			2011
Deferred tax assets:
Net operating loss carryforwards	$	73,129		$	67,395
Research and development tax credit carryforwards		6,770			6,844
Capitalized research		5			117
Stock-based compensation		7,375			7,355
Other		937			1,125

		88,216			82,836
Valuation allowance		(88,216	)		(82,836	)

Net deferred tax assets	$	—		$	—

Summary of the activity related to the Company's unrecognized tax benefits

The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands):


	December 31,
	2012			2011		2010
Beginning balance	$	2,750		$	1,896	$	1,643
Additions based on tax positions related to the current year		153			589		253
Additions for tax positions of prior years		58			265		—
Reductions for tax positions of prior years		(227	)		—		—

Ending balance	$	2,734		$	2,750	$	1,896

Accounts Payable and Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2012

Accounts Payable and Accrued Liabilities [Abstract]

Summary of Accounts payable and accrued liabilities

Accounts payable and accrued liabilities consist of the following (in thousands):


	December 31,
	2012		2011
Accounts payable	$	3,046	$	4,110
Accrued clinical trial expense		615		968
Accrued professional fees		238		299
Deferred rent		94		131
Other		20		7

Total accounts payable and accrued liabilities	$	4,013	$	5,515

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2012

Quarterly Financial Data [Abstract]

Summary of quarterly financial data

The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December 31, 2012.


	2012												2011
	Q1			Q2			Q3			Q4			Q1			Q2			Q3			Q4
Revenues	$	3,243		$	4,574		$	4,907		$	8,931		$	2,200		$	1,514		$	1,857		$	4,748
Expenses	$	10,526		$	10,318		$	10,709		$	12,300		$	11,801		$	11,795		$	11,431		$	11,113
Net loss	$	(7,268	)	$	(5,728	)	$	(5,790	)	$	(3,478	)	$	(9,578	)	$	(10,259	)	$	(9,554	)	$	(6,359	)
Net loss per share	$	(0.13	)	$	(0.11	)	$	(0.11	)	$	(0.07	)	$	(0.21	)	$	(0.20	)	$	(0.18	)	$	(0.12	)

Organization and Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Dec. 31, 2012 Segment shares	Dec. 31, 2011 shares	Dec. 31, 2010 shares
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]
Percentage of revenues	100.00%	100.00%	100.00%
Organization and Summary of Significant Accounting Policies (Additional Textual) [Abstract]
Stock options outstanding \| shares	9,184,346	8,346,190	8,109,901
Number of operating segments \| Segment	1
California Institute for Regenerative Medicine [Member]
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]
Percentage of revenues		18.00%
CHDI Foundation, Inc. [Member]
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]
Percentage of revenues		11.00%
Shire AG [Member]
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]
Percentage of revenues	51.00%
Sigma-Aldrich Corporation [Member]
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]
Percentage of revenues	11.00%	15.00%	59.00%
Dow AgroSciences LLC [Member]
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]
Percentage of revenues	22.00%	43.00%	21.00%
Maximum [Member]
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]
Estimated useful lives of related assets	5 years
Minimum [Member]
Organization and Summary of Significant Accounting Policies (Textual) [Abstract]
Estimated useful lives of related assets	3 years

Investments and Fair Value Measurement (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Schedule of available-for-sale securities
Amortized Cost	$ 73,262	$ 82,612
Gross Unrealized Gains	26	19
Gross Unrealized (Losses)		(7)
Estimated Fair Value	73,288	82,624
Cash equivalents [Member]
Schedule of available-for-sale securities
Amortized Cost	18,836	15,258
Gross Unrealized Gains
Gross Unrealized (Losses)
Estimated Fair Value	18,836	15,258
Marketable securities [Member]
Schedule of available-for-sale securities
Amortized Cost	54,426	67,354
Gross Unrealized Gains	26	19
Gross Unrealized (Losses)		(7)
Estimated Fair Value	54,452	67,366
Money market funds [Member] \| Cash equivalents [Member]
Schedule of available-for-sale securities
Amortized Cost	15,839	15,258
Gross Unrealized Gains
Gross Unrealized (Losses)
Estimated Fair Value	15,839	15,258
U.S. government sponsored entity debt securities [Member] \| Cash equivalents [Member]
Schedule of available-for-sale securities
Amortized Cost	2,997
Gross Unrealized Gains
Gross Unrealized (Losses)
Estimated Fair Value	2,997
U.S. government sponsored entity debt securities [Member] \| Marketable securities [Member]
Schedule of available-for-sale securities
Amortized Cost	54,426	27,020
Gross Unrealized Gains	26
Gross Unrealized (Losses)		(7)
Estimated Fair Value	$ 54,452	27,013
U.S. treasury debt securities [Member] \| Marketable securities [Member]
Schedule of available-for-sale securities
Amortized Cost		751
Gross Unrealized Gains		1
Gross Unrealized (Losses)
Estimated Fair Value		752
Corporate debt securities [Member] \| Marketable securities [Member]
Schedule of available-for-sale securities
Amortized Cost		39,583
Gross Unrealized Gains		18
Gross Unrealized (Losses)
Estimated Fair Value		$ 39,601

Investments and Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Investments and Fair Value Measurement (Textual) [Abstract]
Investments maturity period	2 years
Material unrealized losses		$ 7
Available for sale securities maturity percentage next twelve months	83.00%
Available for sale securities maturity percentage in twelve and twenty four months	17.00%
Available-for-sale securities [Member]
Investments and Fair Value Measurement (Textual) [Abstract]
Material unrealized losses	$ 0
Realized losses	0	0	$ 0
Other-than-temporary impairments of available-for-sale securities	$ 0	$ 0	$ 0

Stock-Based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
Stock-Based Compensation (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Costs and expenses:
Total stock-based compensation expense	$ 5,338	$ 8,081	$ 7,818
Research and development [Member]
Costs and expenses:
Total stock-based compensation expense	2,892	3,769	3,612
General and administrative [Member]
Costs and expenses:
Total stock-based compensation expense	$ 2,446	$ 4,312	$ 4,206

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References + Details

Stock-Based Compensation (Details 1) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Estimating the fair value of the employee stock options
Expected dividend yield of stock	0.00%	0.00%	0.00%
Maximum [Member]
Estimating the fair value of the employee stock options
Risk-free interest rate	1.34%	2.11%	2.60%
Expected life of option (in years)	5 years 6 months 29 days	5 years 4 months 28 days	5 years 4 months 28 days
Expected volatility	0.88%	0.86%	0.84%
Minimum [Member]
Estimating the fair value of the employee stock options
Risk-free interest rate	0.74%	0.93%	1.50%
Expected life of option (in years)	5 years 4 months 24 days	5 years 4 months 21 days	5 years 2 months 23 days
Expected volatility	0.87%	0.83%	0.83%

Stock-Based Compensation (Details 2) - Employee Stock [Member]	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Summary of fair value of the employee stock options and ESPP plan
Expected dividend yield of stock	0.00%	0.00%	0.00%
Maximum [Member]
Summary of fair value of the employee stock options and ESPP plan
Risk-free interest rate	0.30%	0.61%	1.00%
Expected life of option (in years)	2 years	2 years	2 years
Expected volatility	1.37%	0.85%	1.14%
Minimum [Member]
Summary of fair value of the employee stock options and ESPP plan
Risk-free interest rate	0.05%	0.05%	0.20%
Expected life of option (in years)	6 months	6 months	6 months
Expected volatility	0.93%	0.58%	0.62%

Stock-Based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Stock Based Compensation (Textual) [Abstract]
Total compensation cost related to unvested stock options and RSU	$ 9.8
Weighted-average period of unvested stock options and RSU	2 years 9 months 15 days
Stock Based Compensation (Additional Textual) [Abstract]
Capitalized stock-based employee compensation	$ 0.0
Weighted-average estimated fair value per share of options granted	$ 3.76	$ 3.20	$ 3.85
Weighted-average estimated fair value of shares purchased under ESPP plan	$ 2.51	$ 1.62	$ 2.76
Restricted Stock Units (RSUs) [Member]
Stock Based Compensation (Textual) [Abstract]
Total compensation cost related to unvested stock options and RSU	$ 3.5
Weighted-average period of unvested stock options and RSU	2 years 4 months 24 days
2010 Employee Stock Purchase Plan [Member]
Stock Based Compensation (Textual) [Abstract]
Issuance of common stock under employee stock purchase plan, shares	175,000	153,000	134,000
Stock issued under employee stock purchase plans, Average Exercise Price	$ 2.61	$ 3.02	$ 3.34

Major Customers, Partnerships and Strategic Alliances (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Shire AG [Member]
Revenues related to Shire Collaboration:
Amortization of upfront fee	$ 1,986
Research services	9,026
Total	11,012
Revenue related to Sigma Collaboration:
Royalty revenues	0
Sigma-Aldrich Corporation [Member]
Revenue related to Sigma Collaboration:
Royalty revenues	1,288	$ 938	$ 734
License fee and milestone revenues	1,000	671	11,574
Total	$ 2,288	$ 1,609	$ 12,308

Major Customers, Partnerships and Strategic Alliances (Details Textual)	1 Months Ended									12 Months Ended
	Jun. 30, 2012 Targets	Mar. 31, 2012 USD ($)	Jan. 31, 2012 Targets	Apr. 30, 2011 USD ($)	Oct. 31, 2009 USD ($)	Jul. 31, 2007	Jan. 31, 2007 USD ($)	Oct. 31, 2006 USD ($)	Oct. 31, 2005 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2009 shares	Jun. 30, 2010 USD ($)
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Deferred revenue										$ 2,304,000	$ 17,000
Research grants										3,469,000	4,209,000	$ 3,986,000
California Institute for Regenerative Medicine [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Expected amount to be received for research and development					$ 5,200,000
Collaboration Agreement Related Costs and Expenses										$ 1,200,000	2,000,000	1,000,000
Agreement date					2009-10
Funds due under the agreement					$ 14,500,000
Agreement to receive					4 years
Receivables from sale against the grant funded to entity from sale of product										2
CHDI Foundation, Inc. [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Collaboration Agreement Related Costs and Expenses										$ 1,100,000	1,200,000
Funds due under agreement				$ 1,300,000
Agreement date				2011-04
Agreement to receive				1 year
Revenues under the agreement										1,100,000	1,100,000
Funds due under agreement as per amendment										$ 2,100,000
Contractual agreement termination date										Aug. 31, 2012
Michael J. Fox Foundation for Parkinson's Research [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Agreement date							2007-01
Funding received from research grant.										$ 1,900,000
Juvenile Diabetes Research Foundation International [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Agreement date								2006-10
Received for work performed under agreement		$ 800,000
Qualifying Therapeutic Discovery Project Program [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Revenues under the agreement										$ 0	0	1,000,000
Shire AG [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Aggregate number of gene targets \| Targets			7
Number of gene targets \| Targets	5
Number of initial gene targets \| Targets			4
Number of additional gene targets \| Targets	2
Research program to develop laboratory research reagents										6 years
Upfront license fee										$ 13,000,000
Expected amount to be received for research and development										213,500,000
IND or CTA submission amount										8,500,000
Royalty revenues										0
Deferred revenue										11,100,000
Related costs and expenses										7,700,000
Sigma-Aldrich Corporation [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Research program to develop laboratory research reagents						3 years
Upfront license fee					$ 20,000,000
Royalty revenues										1,288,000	938,000	734,000
Common stock, valued					$ 4,900,000
Public offering, common stock shares issued \| shares													636,133
Reduced royalty rate					10.50%
Funding available under the amended agreement					$ 25,000,000
Revenue attributable to research and development										1,000,000	671,000	11,574,000
Dow AgroSciences [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Research program to develop laboratory research reagents									3 years
Royalty revenues									$ 2,300,000
Related costs and expenses										600,000	900,000	700,000
One time license fee earned on exercise of option									$ 6,000,000
Percentage of royalties to be received from sublicensing									25.00%
Minimum sublicense annual fees specific reckoning period									11 years
Fee due									$ 25,300,000
Revenue attributable to research and development										4,700,000	4,500,000	4,400,000
License agreement terms [Member] \| California Institute for Regenerative Medicine [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Revenues under the agreement										1,200,000	1,700,000	1,000,000
License agreement terms [Member] \| Michael J. Fox Foundation for Parkinson's Research [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Revenues under the agreement										0	400,000	400,000
License agreement terms [Member] \| Juvenile Diabetes Research Foundation International [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Revenues under the agreement										800,000	500,000	1,500,000
License agreement terms [Member] \| Sigma-Aldrich Corporation [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Royalty revenues expected to be received					5,000,000
Related costs and expenses										$ 300,000	$ 500,000	$ 1,200,000
License agreement terms [Member] \| Dow AgroSciences [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Royalty revenues									4,000,000
Additional Funding Agreement Terms [Member] \| Michael J. Fox Foundation for Parkinson's Research [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Funds due under the agreement							$ 1,000,000
Funding received from research grant.														$ 900,000
Additional Funding Agreement Terms [Member] \| Juvenile Diabetes Research Foundation International [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Grant funding amount maximum under amended agreement.								$ 3,000,000
Upfront license fee [Member] \| Sigma-Aldrich Corporation [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Upfront license fee					$ 15,100,000
Maximum [Member] \| Dow AgroSciences [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Annual fees									3,000,000
Minimum [Member] \| Dow AgroSciences [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]
Annual fees									$ 250,000

Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Summary of property and equipment
Property and equipment, Gross	$ 4,495	$ 4,329
Less accumulated depreciation	(2,952)	(2,726)
Property and equipment, net	1,543	1,603
Laboratory equipment [Member]
Summary of property and equipment
Property and equipment, Gross	2,950	2,851
Furniture and Fixtures [Member]
Summary of property and equipment
Property and equipment, Gross	499	442
Leasehold Improvements [Member]
Summary of property and equipment
Property and equipment, Gross	$ 1,046	$ 1,036

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References + Details

Property And Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Property and Equipment (Textual) [Abstract]
Depreciation and amortization expenses	$ 660	$ 646	$ 676
Disposition of fixed assets	500
Accumulated Depreciation	400
Write-off of assets	$ 100

Commitments (Details) $ in Thousands	Dec. 31, 2012 USD ($)
Summary of Future minimum payments under contractual obligations
2013	$ 616
2014	417
Thereafter
Total minimum payments	$ 1,033

Commitments (Details Textual) - USD ($) $ in Millions	12 Months Ended
Commitments (Details Textual) - USD ($) $ in Millions	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Commitments (Textual) [Abstract]
Rent expenses	$ 0.6	$ 0.6	$ 0.6

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Summary of stock option activity
Option outstanding, Number of Shares, Beginning Balance	8,374,190
Option granted, Number of Shares	1,352,150
Options exercised, Number of Shares	(326,688)
Options canceled, Number of Shares	(215,306)
Option Outstanding, Number of Shares, Ending Balance	9,184,346	8,374,190
Options vested and expected to vest at December 31, 2012, Number of Shares	8,806,544
Options exercisable at December 31, 2012, Number of Shares	6,435,730
Options outstanding, Weighted-Average Exercise per Share Price, Beginning Balance	$ 6.28
Options granted, Weighted-Average Exercise per Share Price	5.38
Options exercised, Weighted-Average Exercise per Share Price	3.73
Options canceled, Weighted-Average Exercise per Share Price	7.04
Options outstanding, Weighted-Average Exercise per Share Price, Ending Balance	6.21	$ 6.28
Options vested and expected to vest at December 31, 2012, Weighted-Average Exercise Per Share Price	6.25
Options exercisable at December 31, 2012, Weighted Average Exercise per Share Price	$ 6.62
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	6 years 5 months 16 days	6 years 9 months 11 days
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	6 years 5 months 16 days	6 years 9 months 11 days
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	6 years 3 months 22 days
Options exercisable at December 31, 2012, Weighted-Average Remaining Contractual Term	5 years 4 months 28 days
Options outstanding, Aggregate Intrinsic Value	$ 8,821
Options vested and expected to vest at December 31, 2012, Aggregate Intrinsic Value	8,523
Options exercisable at December 31, 2012, Aggregate Intrinsic Value	$ 6,679	$ 1,000	$ 500

Stockholders' Equity (Details 1)	12 Months Ended
Stockholders' Equity (Details 1)	Dec. 31, 2012 $ / shares shares
Summarizes information with respect to stock options outstanding
Number of Shares Outstanding and Exercisable \| shares	9,184,346
Options outstanding Weighted-Average Remaining Contractual life	6 years 5 months 16 days
Number of Shares Exercisable \| shares	6,435,730
Options exercisable Weighted Average Exercise per Share Price	$ 6.62
Range 1 [Member]
Summarizes information with respect to stock options outstanding
Lower Range of Exercise Price	2.04
Upper Range of Exercise Price	$ 3.42
Number of Shares Outstanding and Exercisable \| shares	366,394
Options outstanding Weighted-Average Remaining Contractual life	8 years 3 months 22 days
Number of Shares Exercisable \| shares	107,603
Options exercisable Weighted Average Exercise per Share Price	$ 2.55
Range 2 [Member]
Summarizes information with respect to stock options outstanding
Lower Range of Exercise Price	3.45
Upper Range of Exercise Price	$ 3.45
Number of Shares Outstanding and Exercisable \| shares	1,613,813
Options outstanding Weighted-Average Remaining Contractual life	5 years 11 months 9 days
Number of Shares Exercisable \| shares	1,613,813
Options exercisable Weighted Average Exercise per Share Price	$ 3.45
Range 3 [Member]
Summarizes information with respect to stock options outstanding
Lower Range of Exercise Price	3.61
Upper Range of Exercise Price	$ 5.19
Number of Shares Outstanding and Exercisable \| shares	1,045,182
Options outstanding Weighted-Average Remaining Contractual life	3 years 8 months 1 day
Number of Shares Exercisable \| shares	912,138
Options exercisable Weighted Average Exercise per Share Price	$ 4.47
Range 4 [Member]
Summarizes information with respect to stock options outstanding
Lower Range of Exercise Price	5.26
Upper Range of Exercise Price	$ 5.30
Number of Shares Outstanding and Exercisable \| shares	7,500
Options outstanding Weighted-Average Remaining Contractual life	8 years 11 days
Number of Shares Exercisable \| shares	1,500
Options exercisable Weighted Average Exercise per Share Price	$ 5.30
Range 5 [Member]
Summarizes information with respect to stock options outstanding
Lower Range of Exercise Price	5.35
Upper Range of Exercise Price	$ 5.35
Number of Shares Outstanding and Exercisable \| shares	1,126,273
Options outstanding Weighted-Average Remaining Contractual life	6 years 11 months 5 days
Number of Shares Exercisable \| shares	838,523
Options exercisable Weighted Average Exercise per Share Price	$ 5.35
Range 6 [Member]
Summarizes information with respect to stock options outstanding
Lower Range of Exercise Price	5.41
Upper Range of Exercise Price	$ 5.41
Number of Shares Outstanding and Exercisable \| shares	1,186,650
Options outstanding Weighted-Average Remaining Contractual life	9 years 11 months 5 days
Number of Shares Exercisable \| shares
Options exercisable Weighted Average Exercise per Share Price
Range 7 [Member]
Summarizes information with respect to stock options outstanding
Lower Range of Exercise Price	5.42
Upper Range of Exercise Price	$ 5.66
Number of Shares Outstanding and Exercisable \| shares	60,500
Options outstanding Weighted-Average Remaining Contractual life	6 years 2 months 27 days
Number of Shares Exercisable \| shares	56,333
Options exercisable Weighted Average Exercise per Share Price	$ 5.46
Range 8 [Member]
Summarizes information with respect to stock options outstanding
Lower Range of Exercise Price	5.70
Upper Range of Exercise Price	$ 5.70
Number of Shares Outstanding and Exercisable \| shares	1,132,851
Options outstanding Weighted-Average Remaining Contractual life	7 years 11 months 9 days
Number of Shares Exercisable \| shares	565,551
Options exercisable Weighted Average Exercise per Share Price	$ 5.70
Range 9 [Member]
Summarizes information with respect to stock options outstanding
Lower Range of Exercise Price	5.86
Upper Range of Exercise Price	$ 6.82
Number of Shares Outstanding and Exercisable \| shares	1,054,230
Options outstanding Weighted-Average Remaining Contractual life	5 years 10 months 17 days
Number of Shares Exercisable \| shares	785,006
Options exercisable Weighted Average Exercise per Share Price	$ 6.49
Range 10 [Member]
Summarizes information with respect to stock options outstanding
Lower Range of Exercise Price	6.88
Upper Range of Exercise Price	$ 14.62
Number of Shares Outstanding and Exercisable \| shares	1,590,953
Options outstanding Weighted-Average Remaining Contractual life	4 years 9 months 18 days
Number of Shares Exercisable \| shares	1,555,263
Options exercisable Weighted Average Exercise per Share Price	$ 12.59

Stockholders' Equity (Details 2) - Restricted Stock Units (RSUs) [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2012 USD ($) shares
Summary of Restricted stock unit activity
RSUs Outstanding at December, 31, 2011, Number of Shares	551,667
RSUs awarded	486,750
RSUs released	(1,667)
RSUs forfeited	0
RSUs Outstanding at December, 31, 2012, Number of Shares	1,036,750
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	1 year 9 months 4 days
RSUs outstanding at December 31, 2012, Aggregate Intrinsic Value \| $	$ 6,231
RSUs vested and expected to vest at December 31, 2012, Number of Shares	835,782
RSUs vested and expected to vest at December 31, 2012, Weighted-Average Remaining Contractual Term	1 year 9 months 4 days
RSUs vested and expected to vest at December 31, 2012, Aggregate Intrinsic Value \| $	$ 5,023

Stockholders' Equity (Details Textual) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2011 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) Installment $ / shares shares	Dec. 31, 2011 USD ($) $ / shares shares	Dec. 31, 2010 USD ($) $ / shares shares
Stockholders Equity (Textual) [Abstract]
Share based vesting rights		RSUs vested in equal monthly installments over a two-year service period
Stock options vesting period		2 years
Additional shares authorized under 2004 plan		1,576,644	1,361,332	1,349,832
Weighted-average estimated fair value of shares purchased under ESPP plan \| $ / shares		$ 2.51	$ 1.62	$ 2.76
Options weighted-average estimated fair value per share \| $ / shares		$ 3.76	$ 3.20	$ 3.85
Stockholders Equity (Additional Textual) [Abstract]
Preferred shares authorized		5,000,000
Specified stockholder ownership percentage		10.00%
Purchase price of common stock percent under stock incentive plans for specified stockholder		110.00%
Stock option maximum term for specified stockholder		5 years
Intrinsic value of options exercised \| $		$ 6,679	$ 1,000	$ 500
Aggregate intrinsic values outstanding options \| $		$ 8,821
Aggregate intrinsic values exercisable options		6,435,730
Options vested and expected to vest, aggregate intrinsic value \| $		$ 8,500	$ 100	11,200
Stock options vesting period		2 years
Stock Option Activity [Member]
Stockholders Equity (Textual) [Abstract]
Shares subject to repurchase rights		0
Restricted Stock Units (RSUs) [Member]
Stockholders Equity (Textual) [Abstract]
Restricted stock units issued		486,750
Restricted stock units outstanding		1,036,750	551,667
Aggregate value of shares vested in period \| $		$ 100	$ 200	$ 100
2004 stock incentive plan [Member]
Stockholders Equity (Textual) [Abstract]
Purchase price of common stock percent under stock incentive plans		100.00%
Stock option maximum term		10 years
Stock options vesting period		4 years
Stock options expiration term		10 years
Annual percentage increase in shares authorized		3.00%
Annual increase in number of shares authorized		1,750,000
Share-based compensation arrangement by share-based payment award, vesting portion on second anniversary		0.33
Share-based compensation arrangement by share-based payment award, vesting portion on third anniversary		0.67
Stockholders Equity (Additional Textual) [Abstract]
Stock options vesting period		4 years
2004 stock incentive plan [Member] \| Stock Option Activity [Member]
Stockholders Equity (Textual) [Abstract]
Share based vesting rights		Options granted under the 2004 Plan generally vest over four years at a rate of 25 percent one year from the grant date and one thirty-sixth per month thereafter and expire ten years after the grant, or earlier upon employment termination
Share-based compensation arrangement by share-based payment award, vesting percentage		25.00%
2004 stock incentive plan [Member] \| Restricted Stock Units (RSUs) [Member]
Stockholders Equity (Textual) [Abstract]
Share based vesting rights		These awards will vest as follows: one-third of the award will vest in a series of three successive equal annual installments
Restricted stock units issued		486,750	550,000	10,000
Grant date fair value of restricted stock units issued \| $ / shares		$ 5.41	$ 2.55	$ 6.05
Share-based compensation arrangement by share-based payment award, number of vesting installment \| Installment		3
Share-based compensation arrangement by share-based payment award, vesting portion		0.33
2000 Plan and 2004 Plan [Member]
Stockholders Equity (Textual) [Abstract]
Stock reserved for issuance under 2000 and 2004 plan		6,500,000
Shares reserved for issuance of future awards		2,749,117
2010 Employee Stock Purchase Plan [Member]
Stockholders Equity (Textual) [Abstract]
Stock reserved for issuance under 2000 and 2004 plan		2,100,000
Percentage of common stock purchased		85.00%
Purchase plan offering period		2 years
Purchase plan purchase period		6 months
Shares reserved for issuance of future awards		1,708,315
Common Stock [Member]
Stockholders Equity (Textual) [Abstract]
Public offering, common stock shares issued	6,700,000
Public offering price of common stock issued \| $ / shares	$ 7.70
Net proceeds from issuance under public offering \| $	$ 50,200

Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Deferred tax assets:
Net operating loss carryforwards	$ 73,129	$ 67,395
Research and development tax credit carryforwards	6,770	6,844
Capitalized research	5	117
Stock-based compensation	7,375	7,355
Other	937	1,125
Total Deferred Assets	88,216	82,836
Valuation allowance	(88,216)	(82,836)
Net deferred tax assets

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.

+ References + Details

Income Taxes (Details1) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details1) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Summarizes the activity related to the Company's unrecognized tax benefits
Beginning balance	$ 2,750	$ 1,896	$ 1,643
Additions based on tax positions related to the current year	153	589	253
Additions for tax positions of prior years	58	265
Reductions for tax positions of prior years	(227)
Ending balance	$ 2,734	$ 2,750	$ 1,896

Income Taxes (Details Textual) - USD ($)	12 Months Ended
Income Taxes (Details Textual) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Taxes (Textual) [Abstract]
Increase in deferred tax asset valuation allowance	$ 5,400,000	$ 19,700,000	$ 7,400,000
Deferred tax assets, net operating loss carryforwards for federal	187,100,000
Deferred tax assets, net operating loss carryforwards for state	$ 163,100,000
Operating loss carryforwards, expiration year	2013
Federal research tax credit carryforwards	$ 6,770,000	$ 6,844,000
State research tax credit carryforwards	$ 5,900,000
Tax credit carryforward, expiration year	2018
Income tax accrued penalties and interest	$ 0

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.

+ References + Details

Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Summary of Accounts payable and accrued liabilities
Accounts payable	$ 3,046	$ 4,110
Accrued clinical trial expense	615	968
Accrued professional fees	238	299
Deferred rent	94	131
Other	20	7
Total accounts payable and accrued liabilities	$ 4,013	$ 5,515

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.

+ References + Details

Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
Employee Benefit Plan (Details Textual) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Employee Benefit Plan (Textual) [Abstract]
Defined contribution plan, employer's matching contribution percent	50.00%
Employers matching contribution percentage towards employees contribution	6.00%
Defined contribution plan, maximum employer's contribution per employee	$ 1,000
Aggregate employers contributions to defined contribution plan	$ 100,000	$ 0	$ 0

Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Summary of quarterly financial data
Revenues	$ 8,931	$ 4,907	$ 4,574	$ 3,243	$ 4,748	$ 1,857	$ 1,514	$ 2,200	$ 21,655	$ 10,319	$ 20,805
Expenses	12,300	10,709	10,318	10,526	11,113	11,431	11,795	11,801	43,853	46,140	45,740
Net loss	$ (3,478)	$ (5,790)	$ (5,728)	$ (7,268)	$ (6,359)	$ (9,554)	$ (10,259)	$ (9,578)	$ (22,264)	$ (35,750)	$ (24,854)
Net loss per share	$ (0.07)	$ (0.11)	$ (0.11)	$ (0.13)	$ (0.12)	$ (0.18)	$ (0.20)	$ (0.21)	$ (0.42)	$ (0.71)	$ (0.55)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Investments and Fair Value Measurement (Details 1) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	$ 73,288	$ 82,624
Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	18,836	15,258
Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	54,452	67,366
Money market funds [Member] \| Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	15,839	15,258
U.S. government sponsored entity debt securities [Member] \| Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	2,997
U.S. government sponsored entity debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	54,452	27,013
U.S. treasury debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities		752
Corporate debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities		39,601
Level 1 [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	15,839	15,258
Level 1 [Member] \| Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	15,839	15,258
Level 1 [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 1 [Member] \| Money market funds [Member] \| Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	15,839	15,258
Level 1 [Member] \| U.S. government sponsored entity debt securities [Member] \| Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 1 [Member] \| U.S. government sponsored entity debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 1 [Member] \| U.S. treasury debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 1 [Member] \| Corporate debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 2 [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	57,449	67,366
Level 2 [Member] \| Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	2,997
Level 2 [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	54,452	67,366
Level 2 [Member] \| Money market funds [Member] \| Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 2 [Member] \| U.S. government sponsored entity debt securities [Member] \| Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	2,997
Level 2 [Member] \| U.S. government sponsored entity debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities	54,452	27,013
Level 2 [Member] \| U.S. treasury debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities		752
Level 2 [Member] \| Corporate debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities		39,601
Level 3 [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 3 [Member] \| Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 3 [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 3 [Member] \| Money market funds [Member] \| Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 3 [Member] \| U.S. government sponsored entity debt securities [Member] \| Cash equivalents [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 3 [Member] \| U.S. government sponsored entity debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 3 [Member] \| U.S. treasury debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities
Level 3 [Member] \| Corporate debt securities [Member] \| Marketable securities [Member] \| Available-for-sale securities [Member]
Summary of fair value measurements of cash equivalents and available-for-sale marketable securities
Total cash equivalents and marketable securities